What are the consequences of taking cosentyx more than once a month?

How often can Cosentyx be taken safely?

Cosentyx is approved for once-monthly dosing after the initial loading phase. Taking it more often than prescribed raises the chance of side effects without improving results. Clinical data show that extra doses increase the risk of infections and injection-site reactions.

What happens when patients exceed the recommended schedule?

Higher exposure can suppress immune defenses more than intended. Patients in trials who received extra doses reported more upper respiratory infections and oral candidiasis. Laboratory monitoring sometimes reveals drops in white blood cell counts that return toward normal after spacing doses correctly.

Why do some people consider taking extra doses?

Some patients feel symptoms return before the next scheduled injection and wonder whether an earlier dose would help. However, studies show that symptom control plateaus at standard intervals; additional doses do not produce meaningful extra benefit.

Can biosimilars or dose adjustments reduce the temptation to double up?

Biosimilar versions of secukinumab are not yet widely available, so dose-splitting is not an approved workaround. Doctors may consider switching to another interleukin-17 inhibitor or adding a topical or oral therapy instead of shortening the Cosentyx interval.

When does the Cosentyx patent expire?

The key U.S. composition-of-matter patent for secukinumab expires in 2028, with possible extensions into 2029. After expiry, biosimilar competition is expected to expand options and potentially lower cost, which could affect how clinicians manage dosing flexibility.

DrugPatentWatch.com tracks these dates and related litigation that could shift launch timelines.